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Abstract: 
Extended release Buccoadhesive buccal tablet for delivery of Nisoldipine 
were developed using Progressive hydration technology. Technology 
involves Carbopol 972P (CP), Hypromellose K15M (HPMC) and 
Polycarbophil (PC) in different amounts. Experiments were designed based 
on 32 full factorial design to explore effects of CP and HPMC on 
buccoadhesive strength (BAS) and drug release. Both polymers were found 
to have effect on swelling index, BAS and drug release which was confirmed 
by level of significance (p < 0.05). Using quadratic terms a linear second 
order model that describes a twisted plane of responses were also drawn for 
elucidation of effect of polymers. Three check points were also taken into 
account to validate the polynomial equation. Results show that polymers 
drastically change the drug release mechanism which was confirmed by 
model fitting into dissolution profile. By customizing the formulation by 
optimizing the ratio of polymers, desired release (90%) was obtained in the 
sixth hour and good BAS were obtained for batch F10. 
 
Keywords: Buccoadhesive; Nisoldipine; Factorial design; Polynomial 
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Introduction  
The oral route of drug administration is the most 
preferred route for systemic drug delivery by 
physicians and patients. Though, oral route offers 
distinct advantages over other conventional drug 
delivery routes like topical and parenteral. Peroral 
administration of certain drugs has disadvantages such 
as unpredictable, erratic and incomplete absorption, 
degradation of drug in stomach and hepatic metabolism 
resulting in reduced bioavailability. Thus, several 
alternative routes are constantly being studied for better 
delivery. Buccal route has long been shown as possible 
route of delivery of drugs having poor oral 
bioavailability because of high first pass metabolism or  
 
degradation in the gastrointestinal tract. This route is 
well vascularized draining to the heart directly via the 
internal jugular vein [1]. In the oral mucosal cavity, 
drug can be delivered either by sublingual route or by 
buccal route. Novel dosage forms for buccal delivery 
may be either conventional tablets or sustained release 
systems. These are intended to release the drug within a 
specified period of time including buccoadhesive, 
biodegradable or chewing gum systems. Adhesive 
sustained delivery systems like tablets, gels, and 
patches, have been recommended for buccal drug 
delivery.  
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Prerequisites of such delivery systems are adhesion to 
mucosa for retention and extension of drug delivery. 
Variety of polymers are available for such type of 
delivery system like Chitosan , gelatin, cellulose and its 
derivatives from natural origin, Carbopol, HPMC, 
HPC, PVP , Polycarbophil, Polyoxyethylene and 
thiolated polymers from semisynthetic and synthetic 
origin. Buccoadheisve formulations are available in the 
form of tablets, patches, wafers, lozenge, gels, ointment 
and suspensions. For those drugs that penetrate the oral 
mucosal membranes slowly or incompletely, 
formulation with a penetration enhancer have been 
recommended. 
Nisoldipine is a calcium channel blocker used in the 
treatment of hypertension. It has high and variable 
hepatic clearance with a bioavailability of only 5% and 
elimination half life 7-12 hrs [2]. Drug has low 
molecular weight of 324 D, optimal log P, 3.2 [3] 
indicating it’s delivery is best suited via buccal 
extended release formulations where its bioavailability 
can be enhanced and side effects can be reduced. 
For Extended release buccal formulation, very few 
technologies are found to be commercially viable. 
Buccoadhesive “Progressive hydration technology” is 
the only technology which has been employed for 
tablets and has been successfully commercialized [4,5]. 
This technology provides a bioadhesive tablet that 
progressively hydrates, whereby the inner core of the 
tablet remains protected from moisture and the 
surrounding environment. It involves Carbopol, 
HPMC, Polycarbophil, and Starch as function 
excipients. This study is an attempt to aiming 
development of Buccal adhesive tablet of Nisoldipine 
using Progressive hydration technology studying 
effects of its functional components on BAS and drug 
release. 
 
Materials and Methods 
 
Materials  
Nisoldipine (NS) (99.15% purity) was procured from 
Shandong Boyuan Chemical co, Ltd (Jinan, China), 
Carbopol, Polycarbophil and HPMC were obtained as 
gift samples from Lubrizol Advanced Materials India 
Pvt. Ltd and Colorcon, Goa, India. Directly 
compressible lactose (DCL 11) was obtained from 
Wockhardt Research centre (Aurangabad, India), Talc, 
Sodium lauryl sulphate, Starch, Aerosil 200 and 
Magnesium stearate were procured from S.D.Fine 
chemicals (Mumbai, India). Porcine buccal piece was 
obtained from Deonar abattoir (Mumbai). All other 
reagents and chemicals used were of analytical reagent 
grade. 
 
In vitro drug permeation studies 
The in vitro buccal drug permeation study of NS 
through the porcine buccal mucosa was performed 
using Keshary-Chien type glass diffusion cell at 37°C ± 
0.2°C [6]. Fresh porcine buccal mucosa was mounted 
between the donor and receptor (surface area 3.14 cm2) 
compartments. The suspension of NS in 2 ml of 
simulated salivary fluid, pH 6.8 containing 10 mg of 
NS was placed in the donor compartment, while 
receiver compartment contained 25 ml of 2.0% Sodium 
lauryl sulphate. Two compartments were clamped 
tightly. Solution hydrodynamics in the receptor 
compartment was maintained by stirring with a 
magnetic bead at 50 rpm. One milliliter sample was 
withdrawn at predetermined time intervals and 
analyzed for drug content at 238 nm, after suitable 
dilution using a UV-spectrophotometer (PerkinElmer-
Lambda 25, USA).  
 
Design of experiments: preparation of buccoadhesive 
buccal tablets 
Depending upon the evaluation of prototype 
formulation (data not shown) two polymers were found 
to be having predominant effect on BAS and drug 
release. A central composite design (CCD) for these 
two factors at three levels each (with a = 1) was 
selected to optimize the varied response variables. Both 
factors were varied as required by the experimental 
design and the factor levels were suitably coded (Table 
1). The amounts of other excipients were kept constant 
and directly compressible lactose (DCL) was taken in a 
sufficient quantity to maintain a constant tablet mass of 
100 mg.  
 
Preparation of buccoadhesive tablets 
Buccoadhesive tablets were prepared by a direct 
compression procedure involving two consecutive 
steps. The buccoadhesive drug/polymer mixture was 
mixed homogeneously by sifting through sieve 60 
ASTM. The mixture was then compressed using an 8-
mm, round-shaped flat punch in a single-stroke, 
multistation tablet machine (Karnavati, Mumbai). The 
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tablets were prepared using compositions as given in 
Table 2.  
Table 1. Formulation variables and their levels 
 
Formulation variables and 
levels 
HPMC (X1) CP (X2) 
-1 -1 
0 -1 
1 -1 
-1 0 
0 0 
1 0 
-1 1 
0 1 
1 1 
-1 = 0 mg -1 = 0 mg 
0 = 15 mg 0 = 15 mg 
+1 = 30 mg +1 = 30 mg 
 
Tablet characterization and evaluation 
Ten tablets were powdered and a quantity equivalent to 
10 mg of NS was extracted with 30 mL of methanol. 
The resultant suspension was shaken for 15 minutes 
and contents diluted to 50 mL with methanol and 
filtered through 0.45micron filter. Absorbance of the 
filtrate was measured at λmax of 238 nm 
spectrophotometrically.  
Tablets were also evaluated for hardness (n = 6) using a 
Monsanto type hardness tester (Labline, India), 
friability (n = 10) using a Roche Friabilator (Eletrolab, 
India), weight variation (n = 10) using an electronic 
balance (Shimadzu) and thickness (n = 10) using 
Vernier Callipers (Mitutoyo, India). 
 
Swelling studies 
The swelling properties of the tablets were evaluated 
using swelling index by determination of % swelling 
[6,7]. Each tablet was weighed (W1) and immersed in a 
simulated saliva fluid at pH6.8 for predetermined 
times. After immersing the formulation for specified 
time, the tablets were wiped off to remove excess of 
surface water by using filter paper and weighed (W2) 
[8]. Swelling index was calculated using equation 1: 
 ( ) 100
1
12 ×−=
W
WWIndexSwelling                       (1) 
 
Ex Vivo Buccoadhesive Strength 
A modified balance method was used for determining 
the ex vivo buccoadhesive strength [9]. Fresh porcine 
buccal mucosa was obtained from a local 
slaughterhouse and used within 2 hours of slaughter. 
The mucosal membrane was separated by removing 
underlying fat and loose tissues. The membrane was 
washed with distilled water and then with phosphate 
buffer pH 6.8 at 37°C. The mucosa was cut into pieces 
and washed with phosphate buffer pH 6.8. A piece of 
buccal mucosa was tied to a lower teflon block which 
was placed in a beaker filled with phosphate buffer pH 
6.8 touching mucosal surface at 37°C ± 1°C. The 
buccal tablet was stuck to the upper Teflon block with 
cyanoacrylate glue. The two sides of the balance were 
made equal before the study, by keeping a weight on 
the right-hand pan. A weight of 5 g was removed from 
the right-hand pan, which lowered the pan along with 
the tablet over the mucosa. The balance was kept in 
this position for 5 minutes contact time. The water 
(equivalent to weight) was added slowly with a burette 
(100 drops/min) to the right-hand pan until the tablet 
detached from the mucosal surface. This detachment 
force gave the buccoadhesive strength of the buccal 
tablet in grams. Force of adhesion and bond strength 
parameters were calculated from BAS [10] using 
equation 2 & 3. 
1000
8.9
)(
×
=
StrengtheBioadhesiv
NAdhesionofForce     (2) 
 
AreaSurface
AdhesionofForce
NmStrengthBond =− )( 2    (3) 
 
In vitro drug release 
An in house dissolution method was developed and 
validated. Paddle method (USP XXIII) was used in 
study. The dissolution medium consisted of 500 mL of 
1.0% Sodium Lauryl Sulphate. The release was 
performed at 37°C ± 0.5°C, with a rotation speed of 60 
rpm. Samples (5 mL) were withdrawn at predetermined 
time intervals and replaced with fresh medium. The 
samples were filtered through 0.2-μm Whatman filter 
paper (Whatman, Brentford, UK) and analyzed without 
dilution by UV spectrophotometry at 238 nm. 
 
 
Table 2. Composition of Nisoldipine extended release tablet 
 
Composition F1 F2 F3 F4 F5 F6 F7 F8 F9 
Nisoldipine 10.1 10.1 10.1 10.1 10.1 10.1 10.1 10.1 10.1 
HPMC 15K 0 0 0 15 15 15 30 30 30 
Corn Starch 15 15 15 15 15 15 15 15 15 
DCL 11 67.9 52.9 37.9 52.9 37.9 22.9 37.9 22.9 7.9 
Aerosil 2 2 2 2 2 2 2 2 2 
PC 3 3 3 3 3 3 3 3 3 
CP 0 15 30 0 15 30 0 15 30 
Talc 1 1 1 1 1 1 1 1 1 
Mag stearate 1 1 1 1 1 1 1 1 1 
*HPMC indicates hypromellose; DCL 11, directely compressible lactose monohydrate; CP, carbopol 974P; PC, 
polycarbophil 
 
Stability studies in human saliva 
The stability study of optimized tablets was performed 
in natural human saliva. The human saliva was 
collected from subjects ranging between 18-30 years 
[11]. Buccal tablets were placed in separate petri dishes 
containing 5 mL of human saliva and placed in a 
temperature-controlled oven (Dolphin, India) at 37°C ± 
0.5°C for 7 hours. Tablets were physically examined 
for changes in color and shape, collapsing of the 
tablets, and drug content at regular time intervals of 0, 
1, 2, 3, and 6 hours. 
 
Optimization and data analysis 
For the studied design, the multiple linear regression 
analysis (MLRA) method was applied using the SPSS 
software version 16 (SPSS Inc. USA) to fit the full 
second-order polynomial equation with added 
interaction terms. Polynomial regression results were 
demonstrated for the studied responses [12], using 
equation 4: 
 
Y = b1 + b2X1 + b3X2 + b4X1X2 + b5 X12 +b6X22     (4) 
 
Where, Y is the dependent variable, b1 is the arithmetic 
mean response of the 9 trials. Coefficient b2 is the 
estimated coefficient for the factor X1 and b3 is the 
estimated coefficient for the factor X2. The main 
effects (X1 and X2) represent the average result of 
changing one factor at a time from its low to high 
value. The interaction terms (X1X2) show how the 
response changes when 2 factors interact. The 
polynomial terms (X12 and X22) are included to 
investigate nonlinearity. The values of correlation 
coefficients were set to be statistically significant at 5% 
confidential interval. 
Finally, the prognosis of optimum formulation was 
conducted in two stages; first, a feasible space was 
located and second, an exhaustive grid search was 
conducted to predict the possible solutions using 
Surface and contour plot drawn using and Statistical 
6.1 (StatSoft Inc. USA) software. 
 
Results and Discussion 
Drug content and physical evaluation  
The assay of NS in tablets varied between 97.1 and 
100.2 % (mean ± SD = 98.6 ± 1.2 %). Tablet weight 
varied between 97 and 102 (99.5 ± 2.5 mg), thickness 
between 1.15 and 1.22 mm (1.185 ± 0.035 mm), 
hardness between 3.5 and 5 kg cm–2 (4.25 ± 0.75 kg 
cm–2), and friability ranged between 0.41 and 0.80 % 
(0.605 ± 0.195 %). Hence all physical parameters of 
the compressed matrices were within the permissible 
limits of USP XXIII. 
 
In vitro drug permeation studies 
In-vitro drug permeation studies were conducted to 
find possibility of drug permeation through porcine 
buccal mucosa. Porcine mucosa owing to its most 
resembling nature to human buccal mucosa in terms of 
lipid content and composition; membrane morphology 
and permeability barrier functions; composition and 
structure; and being nonkeratinized similar to human 
buccal mucosa [13] was selected as a model for this 
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study. There was no significant lag time found 
followed by permeation coefficient steady state varying 
from 0.433 to 0.179 cm/sec (Figure 1) with average 
value 0.303 cm/sec. Throughout the study NS 
permeation was found to be in the steady state region. 
 
 
 
Figure 1. Permeation profile of NS through porcine 
buccal mucosa (n=3) 
 
Selection of polymers and technology with suitable 
experimental design 
A numbers of polymers have been used in 
buccoadhesive systems like HPMC, HPC, PVP, 
Polycarbophil, Polyoxyethylene, thiolated polymers, 
Chitosan, gelatin, sodium alginate and other celluloses 
and its derivatives. Amongst all, HPMC and CP have 
been used most widely. Progressive hydration 
technology also uses the same set of polymers [4]. 
HPMC is a non-ioninc polymer and CP is ionic. Such 
combination of polymers is known to provide the 
formulation with controlled drug release along with 
desired buccoadhesive properties [14,15]. Selected 
polymers were also non-toxic, non-irritant, stable at 
buccal and GI pH and compatible with the drug. 
A central composite design (CCD) for two factors for 
CP and HPMC at three levels with a = 1, equivalent to 
32 factorial design was chosen as the experimental 
design. This is an effective second-order experimental 
design associated with minimum of experiments to 
estimate the influence of individual variables (main 
effects) and their second-order effects [14,16,17]. 
Further, this design has an added advantage of 
determining the quadratic response surface, not 
estimable using a factorial design (FD) at two levels 
[18]. 
 
Ex vivo buccoadhesive strength 
The ex vivo buccoadhesive strength with porcine 
buccal mucosa varied from 1.3 g (F1) to 40.2 g (F9). 
Similarly other parameters of bioadhesion were 
calculated and were found to vary between 0.0125 N 
(249 Nm-2) to 0.394 N (7849 Nm-2) as mentioned in 
Table 3. Since selected polymers belong to hydrogel 
group, increase in buccoadhesive strength may be 
attributed to the formation of a strong gel that 
penetrates deeply into the hydrated mucin membrane 
[19]. Hydrogels exist in glass-rubbery transition state 
which has high plasticization property. This property 
provides high surface for maximum contact with mucin 
along with flexibility for interpenetration. Figure 2 
shows that the ex-vivo buccoadhesive strength 
increased linearly with increasing concentration of CP 
or HPMC which may attribute to high interpenetration, 
augmenting high buccoadhesive strength. Such 
observations are concurrent to the observation by Singh 
et. al. and Ponchel et. al. who attributed this 
phenomena to high interpenetration resulting in gelling, 
augmenting high buccoadhesive strength [14,19,20]. 
The results also indicate that the effect of X2 
(concentration of CP) was more significant than the 
effect of X1 (concentration of HPMC). Moreover, a 
synergistic effect was found by interaction of CP and 
HPMC which are similar to that obtained by Singh et. 
al. and Nur et. al. [14,15]. 
 
 
 
 
Figure 2. Buccoadhesive strengths of Nisoldipine 
buccal tablets (F1 to F9) prepared as per centre 
composite design (n=3) 
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Table 3. Buccoadhesive parameters of buccoadhesive Nisoldipine buccal tablets 
 
Parameters F1 F2 F3 F4 F5 F6 F7 F8 F9 
Buccoadhesive 
strength (g) 
1.3 5.1 16.0 3.0 9.8 22.6 11.1 18.9 40.2 
force of adhesion (N) 0.01256 0.05003 0.15696 0.02943 0.09614 0.22171 0.10889 0.18541 0.39436
Bond strength (Nm-2) 249.936 995.84 3124.2 585.788 1913.57 4412.94 2167.42 3690.47 7849.56
Results are in mean ±SD (n=3) 
 
Swelling and erosion studies 
Swelling and erosion studies help in analysis of 
important parameters involving drug release 
mechanism in a matrix system,  possibility of water 
penetration for drug release, lag time of drug release of 
insoluble drug in matrix system and requirement to 
remove residual tablet on complete erosion [21]. 
Swelling and erosion data for formulation F8 is shown 
in Figure 3 which shows that an initial increase in 
swelling occurred till 4 hours followed by 
comparatively steep swelling curve. Matrix erosion 
was also observed to play a role in controlling the drug 
release with an initial lag phase followed by significant 
erosion. Such observation is in concurrence with 
dissolution behavior of F8. 
 
 
 
Figure 3. Degree of swelling and erosion for 
formulation F8 
 
 
In vitro drug release studies 
Dissolution profiles obtained are shown in Figure 4. As 
evident from the degree of swelling and erosion (Figure 
3), the influence of polymer levels are found to be vital 
in regulating the drug release. Drug release profiles of 
formulations show an initial phase of spontaneous 
release of the drug for formulation having insufficient 
polymer amounts to spread network of hydrophilic 
chain around matrix system, demonstrated by batches 
F1 and F4. [14,20,22]. Formulation F2. F3, F5, F6, F7, 
F8 and F9 shows development of hydrophilic gel layer 
surrounding the matrix which control the release of 
drug. In these batches drug is entrapped in the swollen 
matrix and it releases only when matrix starts eroding. 
Several drug release models were used to characterize 
release mechanism. Summary of the drug release 
models used and their correlation coefficients are 
mentioned in Table 4. Correlation coefficient can be 
utilized to find a suitable model. Formulations F1, F6 
and F8 predominantly follow Hopfenberg model, 
applicable for slab shaped matrices. In this model rate 
limiting step for drug release is erosion of matrix itself 
and time dependent internal or external resistances do 
not influence the release of the drug [23]. This may be 
attributed to thin shape of the formulation because of 
which release may happen via erosion mechanism. This 
model has been employed by Katzhender at. Al. and 
Munasur et. al.for thin formulations [24,25]. 
Formulation F2, F3 and F7 follow Higuchi model 
which is most common for homogeneous polymer 
matrices. It describes drug release process based on 
Fick’s law and release being dependent on square root 
of time [26]. Formulation F2 and F9 follow Bankers-
Lonsdale model indicating high polymer amount in 
matrices which swells to great extent and may behave 
structurally close to spheres [27]. Formulation F5 has 
equal amount of CP and HPMC where polymer neither 
swells nor erodes as in case of low polymer containing 
matrices, hence it follows Hixson-Crowell model 
which assumes that tablet may take spherical shape and  
 
 
Table 4. Drug release model fitting to various models and their correlation coefficients 
 
Correlation coefficient (R2) 
Model F1 F2 F3 F4 F5 F6 F7 F8 F9 
Zero order 0.9195 0.9195 0.9360 0.9921 0.8994 0.9224 0.9365 0.9426 0.6509 
First order 0.7393 0.7182 0.7771 0.2498 0.7578 0.8946 0.7606 0.9496 0.9565 
Higuchi 0.9334 0.9471 0.9657 0.9614 0.8382 0.7973 0.9613 0.8341 0.7325 
Hixson-
Crowell 0.7478 0.7132 0.6853 0.7926 0.9296 0.3096 0.7698 0.8635 0.9202 
Banker-
Lonsdale 0.8670 0.9470 0.8870 0.8280 0.8930 0.6780 0.8370 0.6830 0.9890 
Hopfenberg 0.9690 0.9390 0.9300 0.9630 0.9150 0.9790 0.9270 0.9780 0.9180 
Weibull 0.9280 0.9900 0.9760 0.9020 0.9960 0.9760 0.9940 0.7950 0.7420 
Release 
model Hopfenberg 
Higuchi/ 
Banker Higuchi 
Zero 
oredr 
Hixson-
Crowell Hopfenberg Higuchi Hopfenberg Banker 
 
 
dissolution can occur equally from all sides [28].  Only 
batch F4 followed zero order kinetics where the entire 
drug released in less than 4 hours. 
Further drug release profiles were analysed using 
Korsmeyer-Peppa’s model to analyse drug transport 
mechanism based on their release exponent (n) using 
single equation 5: 
 
           nt at
M
M =
∞
                                                       (5) 
Where, Mt is amount of drug released in time t, M∞ is 
amount of drug released in infinite time, a is constant, t 
is time and n is release exponent. When n approximates 
0.5, a Fickian/diffusion-controlled release is implied, 
where n = 0.5 to 1.0 a non-Fickian transport/ 
anomalous transport happen, n = 1 for zero-order (case 
II transport) and n > 1 super case II. In the case of a 
cylinder, n=0.45 instead of 0.5, and 0.89 instead of 1.0 
[29]. 
 
The n varies from 0.0227 to 1.2475 representing huge 
change in drug transport mechanism by change in 
polymer concentration (Table 5). Formulations F1, F2, 
F3, F6 and F7 were found to follow Fickian transport; 
however anomalous transport was observed for batches 
F4, F8 & F9 and Super Class II for F5. None of the 
formulation was found to have unit value for n (Zero 
order kinetic) as it was not observed in multimodel 
analysis. Also Single formulation F5 showed Super 
Class II concurrent to the above result of multimodel 
analysis having dominating Hixson-Crowell model. 
 
 
 
Figure 4. Dissolution profile of Nisoldipine buccal 
extended release tablets (F1-F9) 
 
Table 5. Drug release model fitting to Korsmeyer-peppas's and correlation coefficients 
 
Korsmeyer-peppas's 
Parameters F1 F2 F3 F4 F5 F6 F7 F8 F9 
Release exponent (n) 0.0227 0.0434 0.2648 0.7548 1.2475 0.069 0.4325 0.5353 0.7503 
Kinetic constant (k) 0.9539 0.9204 0.6308 0.2659 0.1069 0.8890 0.4779 0.3805 0.2148 
Correlation coefficient (R2) 0.8635 0.8499 0.8235 0.847 0.8189 0.597 0.6878 0.8482 0.9423 
Transport mechanism Fickian Fickian Fickian Anomolous Super Class II Fickian Fickian Anomolous Anomolous 
 
Values of the kinetic constant (k) showed a declining 
trend with an increase in the level of each polymer, 
construing an appreciable change in the polymer matrix  
with a change in the polymer composition attributed by 
both polymers. Table 5 reveals that the overall rate of 
drug release tends to decrease with an increase in 
concentration of HPMC or CP. 
Formulations having high CP amount were found to 
have initial phase with insignificant drug release. 
Several research findings have supported the fact that a 
mixture of HPMC with CP causes reduced hydration of 
the matrix followed by insufficient channel formation 
for drug release or absence of significant erosion in 
initial phase [14,29,30].  
 
Experimental design approach 
A complete 32 randomized full FD was used in present 
study to evaluate effect of CP and HPMC on 
buccoadhesive strength and drug release in 6 hours. 
Applied 32 FD yields coefficient for one factor and for 
two factors as well. Coefficient for more than one 
factor represents interaction of both factors. Coefficient 
may be positive or negative for synergistic or 
antagonistic effect respectively [32]. A backward 
elimination with statistically significant model was 
generated for buccoadhesive strength and drug release 
in 6 hours. From the model it is evident that both 
synergistic and antagonistic effects on buccoadhesive 
strength and drug release persist. All coefficients were 
found to be significant, having p value less than 0.05 
for buccoadhesive strength while only significant 
synergistic interaction was observed in controlling the 
release on coefficient owing to interaction of CP and 
HPMC (-0.036* HPMC*CP, p = 0.036) 
Based on significant coefficient in the above studies 
polynomial equations obtained (full model) are:  
 
For BAS, 
BAS = 1.978 – (0.193*HPMC) – (0.127*CP) + 
(0.016*HPMC*CP) + (0.016*HPMC*HPMC) + 
(0.020*CP*CP)                                             (6) 
 
 
For drug release in sixth hour 
 
% DR = 101.444 - (0.049*HPMC*CP)              (7) 
 
Equation 6 shows that ex-vivo BAS increased linearly 
with increasing concentration of CP and HPMC with 
overall significance of 0.002 (Table 6). Figure 5 
represents closeness of observed response value to that 
of predicted obtained by polynomial equation. Further 
combined effect of CP and HPMC can be elucidated 
with the help of 3D response surface plot and contour 
plot (Figure 6). A zone lowest of BAS exist closer to 
HPMC than CP elucidating higher BAS imparted by 
CP. A zone of highest BAS exists where CP and 
HPMC are used in high amount. 
 
 
Figure 5. Corelation between actual and predicted 
values of buccoadhesive strength and drug release 
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Equation 7 for drug release demonstrates possible 
effect of individual polymer and their combination. A 
significant synergistic effect is seen when CP and 
HPMC are used together with overall significance of 
0.015 (Table 6). Figure 8 represents observed response 
value to that of predicted obtained by polynomial 
equation. Further combined effect of CP and HPMC 
can be drawn with the help of 3D response surface plot 
and contour plot (Figure 7). 
 
Validation of polynomial equation and selection of 
optimum formulation 
Derivation of polynomial equation depends upon the 
input variables given into it. Further its workability to 
next formulations and reproducibility is to be validated. 
Validation of the polynomial equation was done by 
random scattering of check points analysis by 
developing three formulations within the experimental 
composition range. Upon comparison of the observed 
responses with those of predicted one (Table 7) a 
percentage variation was identified. Percentage 
variation was within the acceptable range ± 5% for 
BAS while ± 2% for drug release. The optimal 
formulation was needed to have 90% drug release and 
sufficient BAS to be  adhered  to  buccal  mucosa. Such  
 
 
Table 6. Coefficients from central composite design for BAS and drug release on 6th hour 
 
 
Buccoadhesive Strength 
(g) Drug release (%) 
Coefficients Value p Value Value p Value 
b 1.978 0.251 101.444 0.000 
b1 -0.193 0.316 0.644 0.378 
b2 -0.127 0.489 1.078 0.183 
b3 0.016 0.019 -0.049 0.036 
b4 0.016 0.045 -0.034 0.17 
b5 0.020 0.027 -0.045 0.097 
R2 0.994 0.972 
Significance 0.002 0.015 
 
 
Table 7. Composition of check points and optimal formulation and variation in predicted and actual 
response 
 
Responses Formulation 
composition Bioadhesion (g) Drug release (%) Formulation 
type HPMC CP Actual* Predicted Percentage variation Actual* Predicted
Percentage 
variation 
5 25 12.4 12.7 2.36 97.1 96.5 -0.62 
25 15 15.9 15.7 -1.27 83 83.9 1.07 Check points 25 25 25.1 26.5 5.28 63.1 64.5 2.17 
Optimal 
(F10) 13 23 15.2 14.5 -4.83 89.6 90.4 0.88 
* mean ±SD (n=3), significance level p=0.05 
 
composition was obtained by putting random values of 
independent variables, keeping CP at higher level for 
higher BAS. An  optimum  formulation  of  HPMC/ CP  
 
 
keeping 13/ 23 was formulated which was found to be 
having acceptable percentage variation from 
predictable responses. 
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Figure 6. Response surface and Contour plot showing effect of CP and HPMC on buccoadhesive strength 
 
 
Conclusion 
Present work included development of extended release 
Buccal tablet for Nisoldipine. Progressive Hydration 
technology was employed utilising HPMC and 
Carbopol as buccoadhesive and release rate controlling 
polymers. Effect of formulation variables were 
evaluated by 32 full FD. High polymer contribution 
was  able  to  control  the  release  and  retain  sufficient 
 
 
 
 
 
 
BAS. The polynomial equations developed for the 
studies were able to reproduce the responses.  Finally, 
it can be concluded that by application of 32 full FD, 
experimental studies can be designed and optimized, 
limiting the number of experiments for target release 
and sufficient BAS. 
 
 
 
 
Figure 7. Response surface and Contour plot showing effect of CP and HPMC on drug release in 6 hours 
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